AGC Biologics Enters into Commercial Manufacturing Agreement with Horizon Pharma plc
Manufacture of teprotumumab for treatment of thyroid eye disease COPENHAGEN, Denmark, May 3, 2018 /PRNewswire/ — AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced…